Augustine Therapeutics

Finance Watch has kept a close eye on venture capital financings in 2025 because of the notable drop in mega-rounds of $100m or more, and there have been none since the last private company edition,

In biotechnology, funding remains the critical catalyst that transforms scientific discoveries into life-changing therapies. At the recent BioEurope conference in Milan, Laura Lane, head of Europe for

Armed with an impressive series A financing that has raked in €77.7m ($84.8m), Augustine Therapeutics has ambitions to be a leading player in the histone deacetylase 6 (HDAC6) inhibition space for the